ClinicalTrials.gg
CompletedNCT03129100Updated Jun 13, 2022Results posted

A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis

A Phase 3 interventional study of Ixekizumab and Placebo in Axial Spondyloarthritis, sponsored by Eli Lilly and Company. Completed at 127 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-13.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
773
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Axial Spondyloarthritis with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Axial Spondyloarthritis · United States.

Enrollment
Largest of 31
773 · median 200
Started
2017
the only one that year
Phase 3
13 of 34
none open now
Registered
13th of 34
by date
Lead sponsor
2 of 34
Eli Lilly and Company

Among the 34 studies in Axial Spondyloarthritis with a site in United States, this one has the largest enrollment of the 31 interventional ones that give a count, is the only one that started in 2017, is one of 13 in phase 3, and was the 13th registered.

Axial Spondyloarthritis

186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

7 of the 34 studies in Axial Spondyloarthritis with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Axial Spondyloarthritis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.

03

Conditions studied

  • Axial Spondyloarthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have completed the final study visit in Study RHBV (NCT02696785), RHBW (NCT02696798), or RHBX (NCT02757352).

(Note: Participants from Study RHBX are not eligible if they permanently discontinued ixekizumab and were receiving a tumor necrosis factor [TNF] inhibitor).

  • Must agree to use a reliable method of .

Exclusion criteria

Exclusion Criteria:

  • Have significant uncontrolled disorders or abnormal laboratory values that, in the opinion of the investigator, pose an unacceptable risk to the participant if product continues to be administered.
  • Have a known to ixekizumab or any component of this investigational product.
  • Had investigational product permanently discontinued during a previous ixekizumab study.
  • Had temporary investigational product interruption at any time during or at the final study visit of a previous ixekizumab study and, in the opinion of the investigator, restarting ixekizumab poses an unacceptable risk for the participant's participation in the study.
  • Have any other condition that, in the opinion of the investigator, renders the participant unable to understand the nature, scope, and possible consequences of the study or precludes the participant from following and completing the protocol.
  • Are currently enrolled in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
773 participants (actual)

Study arms

  • Experimental
    Ixekizumab (IXE) 80Q4W

    Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every four weeks (Q4W).

    Drug: Ixekizumab

  • Experimental
    Ixekizumab (IXE) 80Q2W

    Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every two weeks (Q2W).

    Drug: Ixekizumab

  • Placebo comparator
    Placebo

    Participants received subcutaneous dose of placebo.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY2439821

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who do Not Experience a Flare (Combined Ixekizumab Treatment)

    A flare is defined as Ankylosing Spondylitis Disease Activity Score (ASDAS ≥2.1) at 2 consecutive visits, or ASDAS \>3.5 at any visit during Period 2. ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with high sensitivity C-reactive protein (CRP) as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

    Time frame: Week 64

Secondary outcomes

  1. Percentage of Participants Who do Not Experience a Flare

    A flare is defined as Ankylosing Spondylitis Disease Activity Score (ASDAS ≥2.1) at 2 consecutive visits, or ASDAS \>3.5 at any visit during Period 2. ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with high sensitivity C-reactive protein (CRP) as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

    Time frame: Week 64

  2. Change From Baseline in Modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS)

    The mSASSS is a four-point scoring system for lateral radiographs of the lumbar and cervical spine and has been shown to reliably track disease progression over time, where: 0 = normal; 1 = sclerosis, squaring or erosion; 2 = syndesmophyte; 3 = bony bridge. By the scoring system of mSASSS of the spinal x-rays, a total of 24 sites were scored on the lateral cervical and lumbar spine: the anterior corners of the vertebrae from lower border of C2 to upper border T1 (inclusive), and from lower border of T12 to upper border of S1 (inclusive). Each corner was scored from 0 to 3, resulting in a range from 0 \[no change\] to 72 \[progression\].

    Time frame: Baseline, 2 Years

  3. Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS)20 Response

    ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units (range 0 to 10) in ≥3 of 4 domains, and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. The following ASAS domains are used: Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q5 \& Q6 (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

    Time frame: Week 64

  4. Percentage of Participants Achieving an ASAS40 Response

    ASAS40 is defined as a ≥40% improvement and an absolute improvement from baseline of ≥2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. The following ASAS domains are used: Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q5 \& Q6 (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

    Time frame: Week 64

  5. Percentage of Participants With Change of Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥1.1 Units

    ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness +0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

    Time frame: Week 64

  6. Percentage of Participants With Inactive Disease on the ASDAS (<1.3 Units)

    ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

    Time frame: Week 64

  7. Change From Baseline in the Individual Components of the ASAS Criteria

    Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  8. Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response

    The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.

    Time frame: Week 64

  9. Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)

    High sensitivity CRP is the measure of acute phase reactant. It was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. High sensitivity CRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  10. Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)

    BASMI is a combined index comprising of the following 5 clinical measurements of spinal mobility in participants with radiographic axial spondyloarthritis (rad-axSpA). 1. Lateral Spinal Flexion 2. Tragus-to-wall distance 3. Lumbar Flexion (modified Schober) 4. Maximal intermalleolar distance and 5. Cervical rotation. The BASMI linear result is the average of the 5 assessments and ranges from 0 to 10. The higher the BASMI score the more severe the participant's limitation of movement due to their AS. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  11. Change From Baseline in Chest Expansion in Centimeters

    Chest expansion is the difference, in centimeter (cm), between the circumference of the chest in maximal inspiration and maximal expiration. While participants have their hands resting on or behind the head, the assessor will measure the chest encircled length by centimeter (cm) at the fourth intercostal level anteriorly. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  12. Change From Baseline in Occiput to Wall Distance

    The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  13. Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)

    The MASES is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  14. Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score

    The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  15. Change From Baseline in Severity of Peripheral Arthritis by Tender Joint Count (TJC) Score of 46 Joints

    The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the body). The 46 joints were assessed and classified as tender or not tender. Sum of all joints checked to be tender/painful divided by number of evaluable joints which was multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  16. Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC) Score of 44 Joints

    The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the body). The 44 joints were assessed and classified as swollen or not swollen. Sum of all joints checked to be swollen divided by number of evaluable joints which was multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  17. Percentage of Participants With Anterior Uveitis or Uveitis Flares

    Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.

    Time frame: Week 64

  18. Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score

    The fatigue severity NRS is a participant administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the 1 number that describes their worst level of fatigue during the previous 24 hours. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  19. Change From Baseline on the Quick Inventory of Depressive Symptomatology Self-Report-16 (QIDS-SR16)

    The 16-item QIDS-SR16 version is a widely used validated scale designed to assess the severity of depressive symptoms. The participant was asked to rate the severity and frequency of specific symptoms present over the last 7 days. The QIDS-SR16 total scores range from 0 to 27, where higher scores indicate higher severity of symptoms. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  20. Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score

    The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  21. Change From Baseline in SF-36 Mental Component Summary (MCS) Score

    The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  22. Change From Baseline in ASAS Health Index (ASAS HI)

    The ASAS Health Index (ASAS HI) is a disease specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17 item instrument has scores ranging from 0 (good Health) to 17 (poor Health). Each item consists of 1 question that the participant needs to respond to with either "I agree" (score 1) or "I do not agree (score 0)." A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  23. Change From Baseline in the European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) UK Population-based Index Score

    The European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his/her current health state using a 0- to 100-mm visual analog scale (VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  24. Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores

    The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA participant population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100, with higher scores indicating greater impairment and less productivity. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  25. Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)

    The Jenkins Sleep Evaluation Questionnaire (JSEQ) is a 4 item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Participants report the numbers of days they experience each of these problems in the past month on a 6 point Likert Scale ranging from 0 = "no days" to 5 = "22-30 days. The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

    Time frame: Baseline, Week 64

  26. Percentage of Participants With No New Syndesmophyte Formation

    Percentage of participants with no new syndesmophyte formation was measured using the average of 2 selected readers of 3 readers.

    Time frame: Week 56

  27. Percentage of Participants With Anti-Ixekizumab Antibodies

    A treatment emergent - antidrug antibody (TE-ADA) positive participant is defined as: a) a participant with a \>= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a participant with an increase from the baseline to a level of \>= 1:10. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

    Time frame: Baseline, Week 64

07

Results

Posted Jun 18, 2021

Participant flow

* Lead-In (Period 1): 24 weeks (Week 0 to Week 24) * Extension Period including Double-Blind, Placebo-Controlled, Randomized Withdrawal-Retreatment (RWR) (Period 2): 40 weeks (Week 24 to Week 64) * Long-Term Extension Period (Period 3): 40 weeks (Week 64 to Week 104) * Post-Treatment Follow-Up (Period 4): at least 12 weeks and up to 24 weeks after the date of the participant's ETV or last regularly scheduled visit.

Lead-In Period (Period 1)
Participant flow — Lead-In Period (Period 1)
MilestoneIXE 80Q4W-Lead-in PeriodIXE80Q2W-Lead-in PeriodIXE80Q4W-Group A Extension PeriodIXE80Q2W-Group A Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Extension PeriodPlacebo-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Extension PeriodPBO/IXE80Q2W-Retreatment Extension PeriodPBO/IXE80Q4W-Retreatment Extension PeriodIXE80Q2W-group A Long-term Extension PeriodIXE80Q4W-group A Long-term Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Long-term Extension PeriodPBO-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Long-term Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Long-term Extension PeriodPBO/IXE80Q2W-Retreatment Long-term Extension PeriodPBO/IXE80Q4W-Retreatment Long-term Extension PeriodIXE80Q4W-Group A-Escalation PeriodIXE80Q4W-Randomized Withdrawal Escalation PeriodPBO-Randomized Withdrawal Escalation PeriodPBO-follow-up PeriodIXE80Q4W-follow-up PeriodIXE80Q2W-follow-up Period
Started350423000000000000000000000000
Received at least one dose of study drug348423000000000000000000000000
Completed335406000000000000000000000000
Not completed1517000000000000000000000000
Withdrew: Adverse event26000000000000000000000000
Withdrew: Lost to follow-up20000000000000000000000000
Withdrew: Withdrawal by subject88000000000000000000000000
Withdrew: Lack of efficacy32000000000000000000000000
Withdrew: Surgery programmed01000000000000000000000000
Period2 Extension Period (Group A and B)
Participant flow — Period2 Extension Period (Group A and B)
MilestoneIXE 80Q4W-Lead-in PeriodIXE80Q2W-Lead-in PeriodIXE80Q4W-Group A Extension PeriodIXE80Q2W-Group A Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Extension PeriodPlacebo-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Extension PeriodPBO/IXE80Q2W-Retreatment Extension PeriodPBO/IXE80Q4W-Retreatment Extension PeriodIXE80Q2W-group A Long-term Extension PeriodIXE80Q4W-group A Long-term Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Long-term Extension PeriodPBO-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Long-term Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Long-term Extension PeriodPBO/IXE80Q2W-Retreatment Long-term Extension PeriodPBO/IXE80Q4W-Retreatment Long-term Extension PeriodIXE80Q4W-Group A-Escalation PeriodIXE80Q4W-Randomized Withdrawal Escalation PeriodPBO-Randomized Withdrawal Escalation PeriodPBO-follow-up PeriodIXE80Q4W-follow-up PeriodIXE80Q2W-follow-up Period
Started002553184854530000000000000000000
Received at least one dose of study drug002553184754530000000000000000000
Completed002343124245320000000000000000000
Not completed0021669210000000000000000000
Withdrew: Adverse event00210200000000000000000000
Withdrew: Death00100000000000000000000000
Withdrew: Withdrawal by subject001351120000000000000000000
Withdrew: Physician decision00100000000000000000000000
Withdrew: Lack of efficacy00200000000000000000000000
Withdrew: Lost to follow-up00200000000000000000000000
Withdrew: Experienced flare000056190000000000000000000
Period 2 (Retreatment Extension Period)
Participant flow — Period 2 (Retreatment Extension Period)
MilestoneIXE 80Q4W-Lead-in PeriodIXE80Q2W-Lead-in PeriodIXE80Q4W-Group A Extension PeriodIXE80Q2W-Group A Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Extension PeriodPlacebo-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Extension PeriodPBO/IXE80Q2W-Retreatment Extension PeriodPBO/IXE80Q4W-Retreatment Extension PeriodIXE80Q2W-group A Long-term Extension PeriodIXE80Q4W-group A Long-term Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Long-term Extension PeriodPBO-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Long-term Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Long-term Extension PeriodPBO/IXE80Q2W-Retreatment Long-term Extension PeriodPBO/IXE80Q4W-Retreatment Long-term Extension PeriodIXE80Q4W-Group A-Escalation PeriodIXE80Q4W-Randomized Withdrawal Escalation PeriodPBO-Randomized Withdrawal Escalation PeriodPBO-follow-up PeriodIXE80Q4W-follow-up PeriodIXE80Q2W-follow-up Period
Started000000065910000000000000000
Completed000000065810000000000000000
Not completed00000000010000000000000000
Withdrew: Withdrawal by subject00000000010000000000000000
Period3-Long-Term Extension Period A & B
Participant flow — Period3-Long-Term Extension Period A & B
MilestoneIXE 80Q4W-Lead-in PeriodIXE80Q2W-Lead-in PeriodIXE80Q4W-Group A Extension PeriodIXE80Q2W-Group A Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Extension PeriodPlacebo-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Extension PeriodPBO/IXE80Q2W-Retreatment Extension PeriodPBO/IXE80Q4W-Retreatment Extension PeriodIXE80Q2W-group A Long-term Extension PeriodIXE80Q4W-group A Long-term Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Long-term Extension PeriodPBO-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Long-term Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Long-term Extension PeriodPBO/IXE80Q2W-Retreatment Long-term Extension PeriodPBO/IXE80Q4W-Retreatment Long-term Extension PeriodIXE80Q4W-Group A-Escalation PeriodIXE80Q4W-Randomized Withdrawal Escalation PeriodPBO-Randomized Withdrawal Escalation PeriodPBO-follow-up PeriodIXE80Q4W-follow-up PeriodIXE80Q2W-follow-up Period
Started000000000003061774542300000000000
Completed000000000002871464037210000000000
Not completed0000000000019315590000000000
Withdrew: Adverse event00000000000600000000000000
Withdrew: Withdrawal by subject000000000001274200000000000
Withdrew: Lost to follow-up00000000000101100000000000
Withdrew: Lack of efficacy00000000000000010000000000
Withdrew: Escalated to ixe80q2w000000000000240280000000000
Period 3 (Flare)
Participant flow — Period 3 (Flare)
MilestoneIXE 80Q4W-Lead-in PeriodIXE80Q2W-Lead-in PeriodIXE80Q4W-Group A Extension PeriodIXE80Q2W-Group A Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Extension PeriodPlacebo-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Extension PeriodPBO/IXE80Q2W-Retreatment Extension PeriodPBO/IXE80Q4W-Retreatment Extension PeriodIXE80Q2W-group A Long-term Extension PeriodIXE80Q4W-group A Long-term Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Long-term Extension PeriodPBO-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Long-term Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Long-term Extension PeriodPBO/IXE80Q2W-Retreatment Long-term Extension PeriodPBO/IXE80Q4W-Retreatment Long-term Extension PeriodIXE80Q4W-Group A-Escalation PeriodIXE80Q4W-Randomized Withdrawal Escalation PeriodPBO-Randomized Withdrawal Escalation PeriodPBO-follow-up PeriodIXE80Q4W-follow-up PeriodIXE80Q2W-follow-up Period
Started0000000000000000641115000000
Completed0000000000000000621112000000
Not completed00000000000000000203000000
Withdrew: Escalated to ixe80q2w00000000000000000203000000
Period 3 (Dose Escalation)
Participant flow — Period 3 (Dose Escalation)
MilestoneIXE 80Q4W-Lead-in PeriodIXE80Q2W-Lead-in PeriodIXE80Q4W-Group A Extension PeriodIXE80Q2W-Group A Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Extension PeriodPlacebo-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Extension PeriodPBO/IXE80Q2W-Retreatment Extension PeriodPBO/IXE80Q4W-Retreatment Extension PeriodIXE80Q2W-group A Long-term Extension PeriodIXE80Q4W-group A Long-term Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Long-term Extension PeriodPBO-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Long-term Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Long-term Extension PeriodPBO/IXE80Q2W-Retreatment Long-term Extension PeriodPBO/IXE80Q4W-Retreatment Long-term Extension PeriodIXE80Q4W-Group A-Escalation PeriodIXE80Q4W-Randomized Withdrawal Escalation PeriodPBO-Randomized Withdrawal Escalation PeriodPBO-follow-up PeriodIXE80Q4W-follow-up PeriodIXE80Q2W-follow-up Period
Started000000000000000000007754000
Completed000000000000000000007354000
Not completed00000000000000000000400000
Withdrew: Withdrawal by subject00000000000000000000200000
Withdrew: Physician decision00000000000000000000100000
Withdrew: Lack of efficacy00000000000000000000100000
Period 4 (Post Treatment Follow-up)
Participant flow — Period 4 (Post Treatment Follow-up)
MilestoneIXE 80Q4W-Lead-in PeriodIXE80Q2W-Lead-in PeriodIXE80Q4W-Group A Extension PeriodIXE80Q2W-Group A Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Extension PeriodPlacebo-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Extension PeriodPBO/IXE80Q2W-Retreatment Extension PeriodPBO/IXE80Q4W-Retreatment Extension PeriodIXE80Q2W-group A Long-term Extension PeriodIXE80Q4W-group A Long-term Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Long-term Extension PeriodPBO-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Long-term Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Long-term Extension PeriodPBO/IXE80Q2W-Retreatment Long-term Extension PeriodPBO/IXE80Q4W-Retreatment Long-term Extension PeriodIXE80Q4W-Group A-Escalation PeriodIXE80Q4W-Randomized Withdrawal Escalation PeriodPBO-Randomized Withdrawal Escalation PeriodPBO-follow-up PeriodIXE80Q4W-follow-up PeriodIXE80Q2W-follow-up Period
Started0000000000000000000000025223453
Completed0000000000000000000000022198411
Not completed0000000000000000000000032542
Withdrew: Death00000000000000000000000010
Withdrew: Lost to follow-up00000000000000000000000022
Withdrew: Withdrawal by subject0000000000000000000000032037
Withdrew: Covid 19 restrictions00000000000000000000000020
Withdrew: Missed follow-up00000000000000000000000001
Withdrew: Other00000000000000000000000002

Outcome measures

PrimaryPercentage of Participants Who do Not Experience a Flare (Combined Ixekizumab Treatment)

A flare is defined as Ankylosing Spondylitis Disease Activity Score (ASDAS ≥2.1) at 2 consecutive visits, or ASDAS \>3.5 at any visit during Period 2. ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with high sensitivity C-reactive protein (CRP) as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

Time frame:
Week 64
Reported as:
Number · Percentage of participants
Percentage of Participants Who do Not Experience a Flare (Combined Ixekizumab Treatment)
Percentage of participantsCombined IXEPlacebo
Percentage of Participants Who do Not Experience a Flare (Combined Ixekizumab Treatment)83.354.7
Statistical analysis
  • Combined IXE vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.35 · 95% CI 2.03 to 9.35
SecondaryPercentage of Participants Who do Not Experience a Flare

A flare is defined as Ankylosing Spondylitis Disease Activity Score (ASDAS ≥2.1) at 2 consecutive visits, or ASDAS \>3.5 at any visit during Period 2. ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with high sensitivity C-reactive protein (CRP) as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

Time frame:
Week 64
Reported as:
Number · Percentage of participants
Percentage of Participants Who do Not Experience a Flare
Percentage of participantsIXE80Q4WIXE80Q2WPlacebo
Percentage of Participants Who do Not Experience a Flare83.383.354.7
Statistical analysis
  • IXE80Q4W vs Placebo · Regression, Logistic · p = 0.003 · Odds ratio (or): 4.28 · 95% CI 1.66 to 11.03
  • IXE80Q2W vs Placebo · Regression, Logistic · p = 0.001 · Odds ratio (or): 4.42 · 95% CI 1.77 to 11.02
SecondaryChange From Baseline in Modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS)

The mSASSS is a four-point scoring system for lateral radiographs of the lumbar and cervical spine and has been shown to reliably track disease progression over time, where: 0 = normal; 1 = sclerosis, squaring or erosion; 2 = syndesmophyte; 3 = bony bridge. By the scoring system of mSASSS of the spinal x-rays, a total of 24 sites were scored on the lateral cervical and lumbar spine: the anterior corners of the vertebrae from lower border of C2 to upper border T1 (inclusive), and from lower border of T12 to upper border of S1 (inclusive). Each corner was scored from 0 to 3, resulting in a range from 0 \[no change\] to 72 \[progression\].

Time frame:
Baseline, 2 Years
Reported as:
Mean · Units on a Scale
Change From Baseline in Modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS)
Units on a ScaleIXE80Q4WIXE80Q2WCombined IXE
Change From Baseline in Modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS)0.41 ± 2.1020.23 ± 1.3870.32 ± 1.779
SecondaryPercentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS)20 Response

ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units (range 0 to 10) in ≥3 of 4 domains, and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. The following ASAS domains are used: Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q5 \& Q6 (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

Time frame:
Week 64
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS)20 Response
Percentage of participantsIXE80Q4WIXE80Q2WPlacebo
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS)20 Response81.381.550.9
Statistical analysis
  • IXE80Q4W vs Placebo · Regression, Logistic · p = 0.001 · Odds ratio (or): 4.51 · 95% CI 1.78 to 11.41
  • IXE80Q2W vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.61 · 95% CI 1.88 to 11.31
SecondaryPercentage of Participants Achieving an ASAS40 Response

ASAS40 is defined as a ≥40% improvement and an absolute improvement from baseline of ≥2 units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. The following ASAS domains are used: Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q5 \& Q6 (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).

Time frame:
Week 64
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving an ASAS40 Response
Percentage of ParticipantsIXE80Q4WIXE80Q2WPlacebo
Percentage of Participants Achieving an ASAS40 Response79.279.643.4
Statistical analysis
  • IXE80Q4W vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 5.17 · 95% CI 2.11 to 12.69
  • IXE80Q2W vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 5.23 · 95% CI 2.20 to 12.47
SecondaryPercentage of Participants With Change of Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥1.1 Units

ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness +0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

Time frame:
Week 64
Reported as:
Number · Percentage of participants
Percentage of Participants With Change of Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥1.1 Units
Percentage of participantsIXE80Q4WIXE80Q2WPlacebo
Percentage of Participants With Change of Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥1.1 Units79.274.145.3
Statistical analysis
  • IXE80Q4W vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.60 · 95% CI 1.90 to 11.17
  • IXE80Q2W vs Placebo · Regression, Logistic · p = 0.003 · Odds ratio (or): 3.55 · 95% CI 1.56 to 8.09
SecondaryPercentage of Participants With Inactive Disease on the ASDAS (<1.3 Units)

ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: 0.121×total back pain+0.110×patient global+0.073×peripheral pain/swelling+0.058×duration of morning stiffness+0.579×Ln(CRP+1). (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

Time frame:
Week 64
Reported as:
Number · Percentage of participants
Percentage of Participants With Inactive Disease on the ASDAS (<1.3 Units)
Percentage of participantsIXE80Q4WIXE80Q2WPlacebo
Percentage of Participants With Inactive Disease on the ASDAS (<1.3 Units)60.453.724.5
Statistical analysis
  • IXE80Q4W vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.92 · 95% CI 2.07 to 11.72
  • IXE80Q2W vs Placebo · Regression, Logistic · p = 0.003 · Odds ratio (or): 3.61 · 95% CI 1.57 to 8.32
SecondaryChange From Baseline in the Individual Components of the ASAS Criteria

Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active). Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Individual Components of the ASAS Criteria
Units on a scaleIXE80Q4WIXE80Q2WPlacebo
Patient Global-5.1 ± 0.38-5.0 ± 0.36-3.0 ± 0.36
Spinal Pain-5.1 ± 0.39-4.8 ± 0.37-3.0 ± 0.36
BASFI-4.35 ± 0.316-4.19 ± 0.301-2.79 ± 0.301
Inflammation-5.20 ± 0.336-4.83 ± 0.319-3.03 ± 0.317
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -2.1 · 95% CI -3.1 to -1.1
  • IXE80Q2W vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -2.0 · 95% CI -2.9 to -1.0
  • IXE80Q4W vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -2.1 · 95% CI -3.1 to -1.0
  • IXE80Q2W vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -1.8 · 95% CI -2.8 to -0.8
  • IXE80Q4W vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -1.55 · 95% CI -2.39 to -0.72
  • IXE80Q2W vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -1.40 · 95% CI -2.20 to -0.59
  • IXE80Q4W vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -2.17 · 95% CI -3.05 to -1.28
  • IXE80Q2W vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -1.80 · 95% CI -2.66 to -0.95
SecondaryPercentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response

The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.

Time frame:
Week 64
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response
Percentage of participantsIXE80Q4WIXE80Q2WPlacebo
Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response81.375.945.3
Statistical analysis
  • IXE80Q4W vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 5.34 · 95% CI 2.13 to 13.35
  • IXE80Q2W vs Placebo · Regression, Logistic · p = 0.001 · Odds ratio (or): 4.07 · 95% CI 1.75 to 9.45
SecondaryChange From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)

High sensitivity CRP is the measure of acute phase reactant. It was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. High sensitivity CRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · milligram per liter (mg/L)
Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)
milligram per liter (mg/L)IXE80Q4WIXE80Q2WPlacebo
Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)-12.952 ± 1.4666-11.074 ± 1.3861-5.094 ± 1.3696
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -7.858 · 95% CI -11.729 to -3.987
  • IXE80Q2W vs Placebo · ANCOVA · p = 0.002 · Ls mean difference: -5.979 · 95% CI -9.655 to -2.304
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)

BASMI is a combined index comprising of the following 5 clinical measurements of spinal mobility in participants with radiographic axial spondyloarthritis (rad-axSpA). 1. Lateral Spinal Flexion 2. Tragus-to-wall distance 3. Lumbar Flexion (modified Schober) 4. Maximal intermalleolar distance and 5. Cervical rotation. The BASMI linear result is the average of the 5 assessments and ranges from 0 to 10. The higher the BASMI score the more severe the participant's limitation of movement due to their AS. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)
Units on a scaleIXE80Q4WIXE80Q2WPlacebo
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)-0.69 ± 0.080-0.73 ± 0.075-0.50 ± 0.073
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = 0.062 · Ls mean difference: -0.20 · 95% CI -0.40 to 0.01
  • IXE80Q2W vs Placebo · ANCOVA · p = 0.018 · Ls mean difference: -0.24 · 95% CI -0.43 to -0.04
SecondaryChange From Baseline in Chest Expansion in Centimeters

Chest expansion is the difference, in centimeter (cm), between the circumference of the chest in maximal inspiration and maximal expiration. While participants have their hands resting on or behind the head, the assessor will measure the chest encircled length by centimeter (cm) at the fourth intercostal level anteriorly. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · centimeter (cm)
Change From Baseline in Chest Expansion in Centimeters
centimeter (cm)IXE80Q4WIXE80Q2WPlacebo
Change From Baseline in Chest Expansion in Centimeters0.77 ± 0.2560.53 ± 0.2430.67 ± 0.236
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = 0.757 · Ls mean difference: 0.10 · 95% CI -0.56 to 0.77
  • IXE80Q2W vs Placebo · ANCOVA · p = 0.670 · Ls mean difference: -0.14 · 95% CI -0.77 to 0.50
SecondaryChange From Baseline in Occiput to Wall Distance

The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · cm
Change From Baseline in Occiput to Wall Distance
cmIXE80Q4WIXE80Q2WPlacebo
Change From Baseline in Occiput to Wall Distance-0.78 ± 0.260-0.66 ± 0.239-0.38 ± 0.235
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = 0.236 · Ls mean difference: -0.40 · 95% CI -1.07 to 0.27
  • IXE80Q2W vs Placebo · ANCOVA · p = 0.373 · Ls mean difference: -0.28 · 95% CI -0.92 to 0.35
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)

The MASES is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
Units on a scaleIXE80Q4WIXE80Q2WPlacebo
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)-3.55 ± 0.352-3.62 ± 0.315-3.48 ± 0.302
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = 0.885 · Ls mean difference: -0.07 · 95% CI -0.98 to 0.85
  • IXE80Q2W vs Placebo · ANCOVA · p = 0.735 · Ls mean difference: -0.14 · 95% CI -0.95 to 0.68
SecondaryChange From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score

The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score
Units on a scaleIXE80Q4WIXE80Q2WPlacebo
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score-3.23 ± 0.388-3.34 ± 0.338-2.71 ± 0.335
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = 0.294 · Ls mean difference: -0.53 · 95% CI -1.53 to 0.47
  • IXE80Q2W vs Placebo · ANCOVA · p = 0.164 · Ls mean difference: -0.64 · 95% CI -1.54 to 0.27
SecondaryChange From Baseline in Severity of Peripheral Arthritis by Tender Joint Count (TJC) Score of 46 Joints

The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the body). The 46 joints were assessed and classified as tender or not tender. Sum of all joints checked to be tender/painful divided by number of evaluable joints which was multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Severity of Peripheral Arthritis by Tender Joint Count (TJC) Score of 46 Joints
Units on a scaleIXE80Q4WIXE80Q2WPlacebo
Change From Baseline in Severity of Peripheral Arthritis by Tender Joint Count (TJC) Score of 46 Joints-6.1 ± 0.76-5.3 ± 0.74-4.0 ± 0.85
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = 0.063 · Ls mean difference: -2.1 · 95% CI -4.3 to 0.1
  • IXE80Q2W vs Placebo · ANCOVA · p = 0.211 · Ls mean difference: -1.3 · 95% CI -3.3 to 0.7
SecondaryChange From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC) Score of 44 Joints

The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the body). The 44 joints were assessed and classified as swollen or not swollen. Sum of all joints checked to be swollen divided by number of evaluable joints which was multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC) Score of 44 Joints
Units on a scaleIXE80Q4WIXE80Q2WPlacebo
Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC) Score of 44 Joints-3.6 ± 0.67-3.9 ± 0.59-2.7 ± 0.73
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = 0.334 · Ls mean difference: -0.9 · 95% CI -2.7 to 0.9
  • IXE80Q2W vs Placebo · ANCOVA · p = 0.168 · Ls mean difference: -1.2 · 95% CI -3.0 to 0.5
SecondaryPercentage of Participants With Anterior Uveitis or Uveitis Flares

Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.

Time frame:
Week 64
Reported as:
Number · Percentage of Participants
Percentage of Participants With Anterior Uveitis or Uveitis Flares
Percentage of ParticipantsIXE80Q4WIXE80Q2WPlacebo
Percentage of Participants With Anterior Uveitis or Uveitis Flares4.25.65.7
SecondaryChange From Baseline in the Fatigue Numeric Rating Scale (NRS) Score

The fatigue severity NRS is a participant administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the 1 number that describes their worst level of fatigue during the previous 24 hours. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score
units on a scaleIXE80Q4WIXE80Q2WPlacebo
Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score-4.2 ± 0.31-4.3 ± 0.29-3.5 ± 0.28
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = 0.100 · Ls mean difference: -0.7 · 95% CI -1.5 to 0.1
  • IXE80Q2W vs Placebo · ANCOVA · p = 0.047 · Ls mean difference: -0.8 · 95% CI -1.5 to -0.0
SecondaryChange From Baseline on the Quick Inventory of Depressive Symptomatology Self-Report-16 (QIDS-SR16)

The 16-item QIDS-SR16 version is a widely used validated scale designed to assess the severity of depressive symptoms. The participant was asked to rate the severity and frequency of specific symptoms present over the last 7 days. The QIDS-SR16 total scores range from 0 to 27, where higher scores indicate higher severity of symptoms. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Quick Inventory of Depressive Symptomatology Self-Report-16 (QIDS-SR16)
units on a scaleIXE80Q4WIXE80Q2WPlacebo
Change From Baseline on the Quick Inventory of Depressive Symptomatology Self-Report-16 (QIDS-SR16)-3.68 ± 0.362-3.28 ± 0.344-2.80 ± 0.342
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = 0.068 · Ls mean difference: -0.88 · 95% CI -1.83 to 0.06
  • IXE80Q2W vs Placebo · ANCOVA · p = 0.307 · Ls mean difference: -0.48 · 95% CI -1.40 to 0.44
SecondaryChange From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score

The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score
units on a scaleIXE80Q4WIXE80Q2WPlacebo
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score13.2954 ± 1.121013.1030 ± 1.045710.6934 ± 1.0366
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = 0.079 · Ls mean difference: 2.6021 · 95% CI -0.3011 to 5.5053
  • IXE80Q2W vs Placebo · ANCOVA · p = 0.087 · Ls mean difference: 2.4096 · 95% CI -0.3541 to 5.1734
SecondaryChange From Baseline in SF-36 Mental Component Summary (MCS) Score

The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · units on a scale
Change From Baseline in SF-36 Mental Component Summary (MCS) Score
units on a scaleIXE80Q4WIXE80Q2WPlacebo
Change From Baseline in SF-36 Mental Component Summary (MCS) Score3.1766 ± 0.89684.6404 ± 0.83692.3396 ± 0.8314
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = 0.477 · Ls mean difference: 0.8370 · 95% CI -1.4864 to 3.1605
  • IXE80Q2W vs Placebo · ANCOVA · p = 0.042 · Ls mean difference: 2.3009 · 95% CI 0.0880 to 4.5138
SecondaryChange From Baseline in ASAS Health Index (ASAS HI)

The ASAS Health Index (ASAS HI) is a disease specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17 item instrument has scores ranging from 0 (good Health) to 17 (poor Health). Each item consists of 1 question that the participant needs to respond to with either "I agree" (score 1) or "I do not agree (score 0)." A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · units on a scale
Change From Baseline in ASAS Health Index (ASAS HI)
units on a scaleIXE80Q4WIXE80Q2WPlacebo
Change From Baseline in ASAS Health Index (ASAS HI)-4.64 ± 0.393-4.37 ± 0.368-3.64 ± 0.370
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = 0.058 · Ls mean difference: -0.99 · 95% CI -2.02 to 0.04
  • IXE80Q2W vs Placebo · ANCOVA · p = 0.147 · Ls mean difference: -0.72 · 95% CI -1.71 to 0.26
SecondaryChange From Baseline in the European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) UK Population-based Index Score

The European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his/her current health state using a 0- to 100-mm visual analog scale (VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · units on a scale
Change From Baseline in the European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) UK Population-based Index Score
units on a scaleIXE80Q4WIXE80Q2WPlacebo
Change From Baseline in the European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) UK Population-based Index Score0.2877 ± 0.02520.2847 ± 0.02350.2459 ± 0.0237
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = 0.213 · Ls mean difference: 0.0418 · 95% CI -0.0329 to 0.1164
  • IXE80Q2W vs Placebo · ANCOVA · p = 0.225 · Ls mean difference: 0.0388 · 95% CI -0.0324 to 0.1101
SecondaryChange From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores

The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA participant population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100, with higher scores indicating greater impairment and less productivity. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores
units on a scaleIXE80Q4WIXE80Q2WPlacebo
Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores-43.58 ± 3.329-40.10 ± 3.115-32.96 ± 3.099
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = 0.017 · Ls mean difference: -10.62 · 95% CI -19.28 to -1.95
  • IXE80Q2W vs Placebo · ANCOVA · p = 0.091 · Ls mean difference: -7.14 · 95% CI -15.44 to 1.16
SecondaryChange From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)

The Jenkins Sleep Evaluation Questionnaire (JSEQ) is a 4 item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Participants report the numbers of days they experience each of these problems in the past month on a 6 point Likert Scale ranging from 0 = "no days" to 5 = "22-30 days. The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

Time frame:
Baseline, Week 64
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)
units on a scaleIXE80Q4WIXE80Q2WPlacebo
Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)-4.0 ± 0.50-3.8 ± 0.47-3.6 ± 0.47
Statistical analysis
  • IXE80Q4W vs Placebo · ANCOVA · p = 0.531 · Ls mean difference: -0.4 · 95% CI -1.7 to 0.9
  • IXE80Q2W vs Placebo · ANCOVA · p = 0.743 · Ls mean difference: -0.2 · 95% CI -1.4 to 1.0
SecondaryPercentage of Participants With No New Syndesmophyte Formation

Percentage of participants with no new syndesmophyte formation was measured using the average of 2 selected readers of 3 readers.

Time frame:
Week 56
Reported as:
Number · Percentage of participants
Percentage of Participants With No New Syndesmophyte Formation
Percentage of participantsIXE80Q4WIXE80Q2W
Percentage of Participants With No New Syndesmophyte Formation80.987.8
SecondaryPercentage of Participants With Anti-Ixekizumab Antibodies

A treatment emergent - antidrug antibody (TE-ADA) positive participant is defined as: a) a participant with a \>= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a participant with an increase from the baseline to a level of \>= 1:10. Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

Time frame:
Baseline, Week 64
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-Ixekizumab Antibodies
Percentage of participantsIXE80Q4WIXE80Q2WPlacebo
Percentage of Participants With Anti-Ixekizumab Antibodies4.72.020.0

Adverse events

Collected over Baseline, up to 128 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IXE 80Q4W-Lead-in Period0/348 (0%)10/348 (2.9%)79/348 (22.7%)
IXE80Q2W-Lead-in Period0/423 (0%)12/423 (2.8%)108/423 (25.5%)
IXE80Q4W-Group A Extension Period2/255 (0.8%)12/255 (4.7%)62/255 (24.3%)
IXE80Q2W-Group A Extension Period0/318 (0%)11/318 (3.5%)82/318 (25.8%)
IXE80Q4W-Group B-Randomized Withdrawal Extension Period0/47 (0%)2/47 (4.3%)8/47 (17%)
IXE80Q2W-Group B-Randomized Withdrawal Extension Period0/54 (0%)2/54 (3.7%)17/54 (31.5%)
Placebo-Group B-Randomized Withdrawal Extension Period0/53 (0%)1/53 (1.9%)16/53 (30.2%)
IXE80Q2W/IXE80Q2W-Retreatment Extension Period0/6 (0%)1/6 (16.7%)0/6 (0%)
IXE80Q4W/IXE80Q4W-Retreatment Extension Period0/5 (0%)0/5 (0%)4/5 (80%)
PBO/IXE80Q2W-Retreatment Extension Period0/9 (0%)0/9 (0%)2/9 (22.2%)
PBO/IXE80Q4W-Retreatment Extension Period0/10 (0%)0/10 (0%)1/10 (10%)
IXE80Q2W-group A Long-term Extension Period0/306 (0%)15/306 (4.9%)52/306 (17%)
IXE80Q4W-group A Long-term Extension Period0/177 (0%)3/177 (1.7%)37/177 (20.9%)
IXE80Q2W-Group B-Randomized Withdrawal Long-term Extension Period0/45 (0%)1/45 (2.2%)8/45 (17.8%)
IXE80Q4W-Group B-Randomized Withdrawal Long-term Extension Period0/42 (0%)1/42 (2.4%)6/42 (14.3%)
PBO-Group B-Randomized Withdrawal Long-term Extension Period0/30 (0%)0/30 (0%)9/30 (30%)
IXE80Q2W/IXE80Q2W-Retreatment Long-term Extension Period0/6 (0%)0/6 (0%)0/6 (0%)
IXE80Q4W/IXE80Q4W-Retreatment Long-term Extension Period0/4 (0%)0/4 (0%)3/4 (75%)
PBO/IXE80Q2W-Retreatment Long-term Extension Period0/11 (0%)0/11 (0%)6/11 (54.5%)
PBO/IXE80Q4W-Retreatment Long-term Extension Period0/15 (0%)0/15 (0%)5/15 (33.3%)
IXE80Q4W-Group A-Escalation Period0/77 (0%)1/77 (1.3%)6/77 (7.8%)
IXE80Q4W-Randomized Withdrawal Escalation Period0/5 (0%)0/5 (0%)2/5 (40%)
PBO-randomized Withdrawal Escalation Period0/4 (0%)0/4 (0%)0/4 (0%)
PBO-follow-up Period0/25 (0%)0/25 (0%)0/25 (0%)
IXE80Q4W-follow-up Period1/223 (0.4%)3/223 (1.3%)14/223 (6.3%)
IXE80Q2W-follow-up Period0/453 (0%)2/453 (0.4%)27/453 (6%)
Most frequent serious events
Showing 10 of 77
Most frequent serious events
EventIXE 80Q4W-Lead-in PeriodIXE80Q2W-Lead-in PeriodIXE80Q4W-Group A Extension PeriodIXE80Q2W-Group A Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Extension PeriodPlacebo-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Extension PeriodPBO/IXE80Q2W-Retreatment Extension PeriodPBO/IXE80Q4W-Retreatment Extension PeriodIXE80Q2W-group A Long-term Extension PeriodIXE80Q4W-group A Long-term Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Long-term Extension PeriodPBO-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Long-term Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Long-term Extension PeriodPBO/IXE80Q2W-Retreatment Long-term Extension PeriodPBO/IXE80Q4W-Retreatment Long-term Extension PeriodIXE80Q4W-Group A-Escalation PeriodIXE80Q4W-Randomized Withdrawal Escalation PeriodPBO-randomized Withdrawal Escalation PeriodPBO-follow-up PeriodIXE80Q4W-follow-up PeriodIXE80Q2W-follow-up Period
InfluenzaInfections and infestations0/3480/4230/2550/3180/470/540/531/60/50/90/100/3060/1770/450/420/300/60/40/110/150/770/50/40/250/2230/453
Ovarian germ cell teratoma benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/920/1300/680/951/100/140/150/20/10/20/20/910/470/110/90/90/20/10/30/30/210/20/30/80/570/136
UreterolithiasisRenal and urinary disorders0/3480/4231/2550/3180/470/540/530/60/50/90/101/3060/1770/451/420/300/60/40/110/150/770/50/40/250/2230/453
Acute myocardial infarctionCardiac disorders0/3480/4230/2550/3180/470/540/530/60/50/90/101/3060/1771/450/420/300/60/40/110/150/770/50/40/250/2230/453
Compression fractureInjury, poisoning and procedural complications0/3480/4230/2550/3181/470/540/530/60/50/90/100/3060/1770/450/420/300/60/40/110/150/770/50/40/250/2230/453
Soft tissue inflammationGeneral disorders0/3480/4230/2550/3180/470/541/530/60/50/90/100/3060/1770/450/420/300/60/40/110/150/770/50/40/250/2230/453
Chronic tonsillitisInfections and infestations0/3480/4230/2550/3180/471/540/530/60/50/90/100/3060/1770/450/420/300/60/40/110/150/770/50/40/250/2230/453
Clostridium difficile colitisInfections and infestations1/3480/4230/2550/3180/471/540/530/60/50/90/100/3060/1770/450/420/300/60/40/110/150/770/50/40/250/2230/453
MyelopathyNervous system disorders0/3480/4230/2550/3180/471/540/530/60/50/90/100/3060/1770/450/420/300/60/40/110/150/770/50/40/250/2230/453
Myocardial infarctionCardiac disorders0/3480/4231/2550/3180/470/540/530/60/50/90/100/3061/1770/450/420/300/60/40/110/151/770/50/40/250/2230/453
Most frequent other events
Showing 10 of 30
Most frequent other events
EventIXE 80Q4W-Lead-in PeriodIXE80Q2W-Lead-in PeriodIXE80Q4W-Group A Extension PeriodIXE80Q2W-Group A Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Extension PeriodPlacebo-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Extension PeriodPBO/IXE80Q2W-Retreatment Extension PeriodPBO/IXE80Q4W-Retreatment Extension PeriodIXE80Q2W-group A Long-term Extension PeriodIXE80Q4W-group A Long-term Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Long-term Extension PeriodPBO-Group B-Randomized Withdrawal Long-term Extension PeriodIXE80Q2W/IXE80Q2W-Retreatment Long-term Extension PeriodIXE80Q4W/IXE80Q4W-Retreatment Long-term Extension PeriodPBO/IXE80Q2W-Retreatment Long-term Extension PeriodPBO/IXE80Q4W-Retreatment Long-term Extension PeriodIXE80Q4W-Group A-Escalation PeriodIXE80Q4W-Randomized Withdrawal Escalation PeriodPBO-randomized Withdrawal Escalation PeriodPBO-follow-up PeriodIXE80Q4W-follow-up PeriodIXE80Q2W-follow-up Period
LeukopeniaBlood and lymphatic system disorders1/3480/4230/2552/3180/470/540/530/61/50/90/102/3060/1770/450/420/300/61/40/110/150/770/50/40/250/2231/453
ToothacheGastrointestinal disorders1/3481/4231/2551/3180/471/540/530/60/50/90/101/3060/1770/450/420/300/61/40/110/151/770/50/40/250/2230/453
Neutrophil count decreasedInvestigations0/3481/4230/2550/3181/470/540/530/61/50/90/100/3060/1770/451/420/300/61/40/110/150/770/50/40/250/2230/453
EnthesopathyMusculoskeletal and connective tissue disorders3/3483/4231/2550/3181/471/540/530/60/50/90/100/3060/1770/450/420/300/61/40/110/150/770/50/40/250/2230/453
Covid-19Infections and infestations0/3480/4230/2550/3180/470/540/530/60/50/90/103/3060/1770/450/421/300/60/40/110/150/771/50/40/250/2233/453
Gastrointestinal viral infectionInfections and infestations0/3480/4230/2550/3180/470/540/530/61/50/90/100/3060/1770/450/420/300/60/40/110/150/770/50/40/250/2230/453
NasopharyngitisInfections and infestations27/34840/42327/25530/3182/474/547/530/61/51/90/1019/30617/1772/451/423/300/60/41/112/152/771/50/40/254/2236/453
Foreign body in eyeInjury, poisoning and procedural complications0/3480/4230/2550/3180/470/540/530/61/50/90/100/3060/1770/450/420/300/60/40/110/150/770/50/40/250/2230/453
Back painMusculoskeletal and connective tissue disorders9/34815/4233/2553/3181/473/542/530/61/51/90/102/3061/1770/450/420/300/60/40/110/150/770/50/40/252/2232/453
Upper respiratory tract infectionInfections and infestations16/34822/4237/25513/3182/474/542/530/60/51/90/108/3063/1772/451/422/300/60/40/110/152/770/50/40/252/2231/453

Baseline characteristics

All randomized participants from extension period (period 2).

Age, Categorical
Age, Categorical(Participants)IXE80Q4W-Group A Extension PeriodIXE80Q2W-Group A Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Extension PeriodPlacebo-Group B-Randomized Withdrawal Extension PeriodTotal
<=18 years000000
Between 18 and 65 years240302485352695
>=65 years151601133
Sex: Female, Male
Sex: Female, Male(Participants)IXE80Q4W-Group A Extension PeriodIXE80Q2W-Group A Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Extension PeriodPlacebo-Group B-Randomized Withdrawal Extension PeriodTotal
Female6895101415202
Male187223384038526
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IXE80Q4W-Group A Extension PeriodIXE80Q2W-Group A Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Extension PeriodPlacebo-Group B-Randomized Withdrawal Extension PeriodTotal
Hispanic or Latino618671411179
Not Hispanic or Latino166204313539475
Unknown or Not Reported2828105374
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IXE80Q4W-Group A Extension PeriodIXE80Q2W-Group A Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Extension PeriodPlacebo-Group B-Randomized Withdrawal Extension PeriodTotal
American Indian or Alaska Native141125436
Asian5450151513147
Native Hawaiian or Other Pacific Islander000000
Black or African American020002
White183247313135527
More than one race3803115
Unknown or Not Reported100001
Region of Enrollment
Region of Enrollment(Participants)IXE80Q4W-Group A Extension PeriodIXE80Q2W-Group A Extension PeriodIXE80Q4W-Group B-Randomized Withdrawal Extension PeriodIXE80Q2W-Group B-Randomized Withdrawal Extension PeriodPlacebo-Group B-Randomized Withdrawal Extension PeriodTotal
Argentina111811233
Romania130105
Hungary321107
United States143013250
Czechia373554485
Japan7913121
United Kingdom4601011
Spain5401010
Russia163067665
Canada321028
Netherlands020002
South Korea2823107876
Austria110103
Taiwan171635243
Finland050128
Brazil71600023
Poland506713713150
Italy010001
Mexico40385118102
Israel530019
France440008
Germany231028
08

Study locations

127 sites
  • Arizona Arthritis & Rheumatology Research
    Phoenix, Arizona 85032, United States
  • Care Access Research - Huntington Beach
    Huntington Beach, California 92648, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • Arthritis Assoc. & Osteoporosis Ctr of Colorado Springs, LLC
    Colorado Springs, Colorado 80920, United States
  • Clinical Research Center of CT/NY
    Danbury, Connecticut 06810, United States
  • Arthritis Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
  • Sarasota Arthritis Center
    Sarasota, Florida 34239, United States
  • Marietta Rheumatology
    Marietta, Georgia 30060, United States
  • Institute of Arthritis Research
    Idaho Falls, Idaho 83404, United States
  • Center for Arthritis & Osteoporosis
    Elizabethtown, Kentucky 42701, United States
  • Klein and Associates MD, PA
    Cumberland, Maryland 21502, United States
  • Klein and Associates MD, PA
    Hagerstown, Maryland 21740, United States
  • Arthritis Consultants Inc.
    Saint Louis, Missouri 63141, United States
  • Glacier View Research Institute
    Kalispell, Montana 59901, United States
  • Physician Research Collaboration, LLC
    Lincoln, Nebraska 68516, United States
  • Shanahan Rheumatology & Immunotherapy, PLLC
    Raleigh, North Carolina 27617, United States
  • Carolina Arthritis Associates
    Wilmington, North Carolina 28401, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Articularis Healthcare Group, INC dba Columbia Arthritis Ctr
    Columbia, South Carolina 29204, United States
  • Articularis Healthcare d/b/a/ Low Country Rheumatology, PA
    Summerville, South Carolina 29486, United States
  • Univ of Texas Health Science Center - Houston
    Houston, Texas 77030, United States
  • Arthritis Northwest PLLC
    Spokane, Washington 99204, United States
  • Clinica Adventista de Belgrano
    Ciudad de Buenos Aires, Buenos Aires C1430EGF, Argentina
  • CER Instituto Medico
    Quilmes, Buenos Aires B1878DVC, Argentina
  • Centro de Enfermedades del Higado y Aparato Digestivo
    Rosario, Santa Fe S2000CFJ, Argentina
  • Centro Medico Privado de Reumatologia
    San Miguel de Tucuman, Tucuman T4000AXL, Argentina
  • Consultorios Reumatologicos Pampa
    Ciudad Autonoma de Buenos Aire, C1428DZF, Argentina
  • CIR Centro de Investigacions Reumatologicas
    San Miguel de Tucuman, 4000, Argentina
  • KH der Barmherzigen Schwestern Wien BetriebsGesmbH
    Wien, 1060, Austria
  • CMIP - Centro Mineiro de Pesquisa
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • EDUMED - Educação em Saúde Ltda.
    Curitiba, Paraná 80440-080, Brazil
  • LMK Serviços Médicos S/S
    Porto Alegre, Rio Grande Do Sul 90540-000, Brazil
  • CCBR Brasil Centro de Analises e Pesquisas Clínicas LTDA
    Rio de Janeiro, RJ 22271-100, Brazil
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, RS 90035-903, Brazil
  • Cpclin Centro de Pesquisas Clinicas
    Sao Paulo, São Paulo 01228-200, Brazil
  • CIP - Centro Internacional de Pesquisa
    Goiás, 74110-120, Brazil
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • St. Clare's Mercy Hospital
    St. John's, Newfoundland and Labrador A1C 5B8, Canada
  • Centre de Recherche Musculo-Squelettique
    Trois-Rivieres, Quebec G8Z 1Y2, Canada
  • Group de recherche en maladies osseuses
    Quebec, G1V 3M7, Canada
  • Revmaclinic, s.r.o
    Brno, 611 41, Czechia
  • Interni a revmatologicka ambulance, Inrea s.r.o.
    Ostrava, 703 00, Czechia
  • Arthrohelp s.r.o
    Pardubice, 530 02, Czechia
  • Revmatologicky ustav
    Praha 2, 128 50, Czechia
  • MEDICAL PLUS, s.r.o.
    Uherske Hradiste, 686 01, Czechia
  • Helsinki University Hospital, HYKS
    Helsinki, 00029, Finland
  • Terveystalo Kamppi
    Helsinki, 00100, Finland
  • Kiljava Medical Research
    Hyvinkaa, 05800, Finland
  • Hôpital Trousseau, CHRU de Tours
    Chambray-lès-Tours, 37170, France
  • Centre hospitalier universitaire Lapeyronie
    Montpellier Cedex 5, 34295, France
  • Nouvel Hôpital Orléans La Source
    Orleans CEDEX 2, 45067, France
  • Rheumazentrum Prof. Neeck
    Bad Doberan, Mecklenburg-Vorpommern 18209, Germany
  • Rheumazentrum Ruhrgebiet
    Herne, Nordrhein-Westfalen 44649, Germany
  • Charité Universitätsmedizin Berlin
    Berlin, 12203, Germany
  • HRF Hamburger Rheuma Forschungszentrum
    Hamburg, 20095, Germany
  • Revita Reumatologiai Kft.
    Budapest, 1027, Hungary
  • Vital Medical Center
    Veszprem, 8200, Hungary
  • Barzilai Medical Center
    Ashkelon, 7830604, Israel
  • Rambam Medical Center
    Haifa, 3109601, Israel
  • Rabin Medical Center
    Petach Tikva, 4941492, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • Arcispedale Santa Maria Nuova Azienda Ospedaliera di Reggio Emilia
    Reggio Emilia, 42123, Italy
  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
  • Kagawa University Hospital
    Kita-gun, Kagawa 761-0793, Japan
  • Kochi Medical School Hospital
    Nankoku, Kochi 783-8505, Japan
  • Kuwana City Medical Center
    Kuwana, Mie 511-0061, Japan
  • Sasebo Chuo Hospital
    Sasebo, Nagasaki 857-1195, Japan
  • Osaka University Hospital
    Suita-shi, Osaka 565 0871, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8431, Japan
  • St. Lukes International Hospital
    Chuo-Ku, Tokyo 104 8560, Japan
  • Japanese Red Cross Okayama Hospital
    Okayama, 700-8607, Japan
  • Osaka City General Hospital
    Osaka, 534-0021, Japan
  • Osaka City University Hospital
    Osaka, 545-8586, Japan
  • Yamagata University Hospital
    Yamagata, 990-9585, Japan
  • Kyung Hee University Hospital
    Seoul, Korea 02447, Korea, Republic of
  • Seoul St. Mary's Hospital
    Seoul, Korea 06591, Korea, Republic of
  • Asan Medical Center
    Songpa-gu, Seoul 05505, Korea, Republic of
  • Chungnam National University Hospital
    Daejeon, 35015, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Hanyang University Medical Center
    Seoul, 04763, Korea, Republic of
  • Konkuk University Hospital
    Seoul, 05030, Korea, Republic of
  • Kyunghee University Hospital at Gangdong
    Seoul, 05278, Korea, Republic of
  • Gangnam Severance Hospital
    Seoul, 06273, Korea, Republic of
  • Seoul Municipal Boramae Hospital
    Seoul, 07061, Korea, Republic of
  • Ctro Inv en Artritis y Osteoporosis SC
    Mexicali, Baja California 21200, Mexico
  • Unidad de Investigacion en Enfermedades Cronico Degenerative
    Guadalajara, Jalisco 44620, Mexico
  • Clinica en Investigación en Reumatologia y Obesidad S.C.
    Guadalajara, Jalisco 44650, Mexico
  • Hospital Universitario de Monterrey
    Monterrey, Nuevo Leon 64460, Mexico
  • Centro de Alta Especialidad Reumatologia Inv del Potosi SC
    San Luis Potosi, SLP 78213, Mexico
  • Medical Care and Research, S.A. de C.V.
    Merida, Yucatan 97070, Mexico
  • Investigación y Biomedicina de Chihuahua, SC
    Chihuahua, 31000, Mexico
  • Academisch Medisch Centrum
    Amsterdam, 1105 AZ, Netherlands
  • Antonius Ziekenhuis
    Sneek, 8601 ZK, Netherlands
  • NZOZ ZDROWIE Osteo-Medic
    Bialystok, 15-351, Poland
  • Szpital Uniwersytecki nr 2 im. dr J. Biziela
    Bydgoszcz, 85-168, Poland
  • Centrum Kliniczno-Badawcze
    Elblag, 82-300, Poland
  • Centrum Leczenia Osteoporozy Klinika Zdrowej Kosci
    Lodz, 90-558, Poland
  • Lecznica MAK-MED, NZOZ
    Nadarzyn, 05-830, Poland
  • Prywatna Praktyka Lekarska P. Hrycaj
    Poznan, 61-397, Poland

Showing the first 100 of 127 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Braun J, Kiltz U, Deodhar A, Tomita T, Dougados M, Bolce R, Sandoval D, Lin CY, Walsh J. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. RMD Open. 2022 Jul;8(2):e002165. doi: 10.1136/rmdopen-2021-002165. PubMed 35853675 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in May 2020, 36 months.

Results were first posted in Jun 2021, 1 year after primary completion.

Of 20 phase 3 interventional studies under Axial Spondyloarthritis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 39. This study's 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2017
First posted
Apr 26, 2017
StartActual
May 9, 2017
Primary completionActual
May 26, 2020
CompletionActual
May 27, 2021
Results first posted
Jun 18, 2021
Last update
Jun 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03129100
Responsible party
Sponsor
First posted
Apr 26, 2017
Start date
May 9, 2017
Primary completion
May 26, 2020
Completion
May 27, 2021
Results posted
Jun 18, 2021
Last update
Jun 13, 2022

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion